Loading...
XSHE300015
Market cap17bUSD
Dec 20, Last price  
14.06CNY
1D
0.57%
1Q
44.35%
Jan 2017
5.79%
IPO
9.25%
Name

Aier Eye Hospital Group Co Ltd

Chart & Performance

D1W1MN
XSHE:300015 chart
P/E
38.68
P/S
6.38
EPS
0.36
Div Yield, %
0.55%
Shrs. gr., 5y
6.43%
Rev. gr., 5y
20.52%
Revenues
20.37b
+26.43%
191,188,834314,903,815439,120,734606,450,103864,877,4501,310,624,4721,640,130,4501,984,967,2872,402,047,6163,165,580,4714,000,401,6715,962,845,5598,008,573,9549,990,103,97611,912,409,98415,000,809,43816,109,946,68720,367,156,738
Net income
3.36b
+33.07%
14,591,52138,979,51661,366,55592,489,402120,309,791171,927,760182,546,813223,495,554309,186,277428,043,981557,467,244742,514,5371,008,937,3481,378,920,9701,723,805,3352,323,343,9572,524,230,8403,358,871,535
CFO
5.87b
+30.76%
36,904,48992,187,299121,174,149169,137,874239,966,170257,108,449301,818,986412,651,458453,683,706522,168,231675,098,1661,330,404,5121,399,870,3982,078,432,7343,343,611,3254,084,103,9584,490,674,8115,871,890,091
Dividend
Jun 06, 20240.15002 CNY/sh
Earnings
Apr 24, 2025

Profile

Aier Eye Hospital Group Co., Ltd. operates eye care hospitals and institutions. The company offers medical services in the areas of fundus diseases, optometry, refractive correction, glaucoma, corneal diseases, and cataract. It also provides training course for cataract prevention and treatment. The company operates approximately 500 ophthalmic hospitals in mainland China, 86 ophthalmic hospitals in Europe, 1 ophthalmic hospital in the United States, 7 ophthalmic hospitals in Hong Kong, and 12 ophthalmic hospitals in Southeast Asia. The company was founded in 2007 and is headquartered in Changsha, China.
URL
https://www.aierchina.com/
IPO date
Oct 30, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
20,367,157
26.43%
16,109,947
7.39%
15,000,809
25.93%
Cost of revenue
12,958,718
10,306,961
9,323,394
Unusual Expense (Income)
NOPBT
7,408,438
5,802,985
5,677,416
NOPBT Margin
36.37%
36.02%
37.85%
Operating Taxes
895,023
646,059
677,852
Tax Rate
12.08%
11.13%
11.94%
NOPAT
6,513,415
5,156,926
4,999,564
Net income
3,358,872
33.07%
2,524,231
8.65%
2,323,344
34.78%
Dividends
(717,651)
(648,731)
(618,226)
Dividend yield
0.49%
0.29%
0.16%
Proceeds from repurchase of equity
(564,655)
2,389
5,279
BB yield
0.39%
0.00%
0.00%
Debt
Debt current
850,367
1,111,973
2,321,040
Long-term debt
7,941,074
6,771,035
6,251,362
Deferred revenue
1
1
Other long-term liabilities
45,591
33,750
109,676
Net debt
1,087,906
498,542
2,704,469
Cash flow
Cash from operating activities
5,871,890
4,490,675
4,084,104
CAPEX
(1,459,709)
Cash from investing activities
Cash from financing activities
(2,509,722)
390,433
FCF
5,083,223
4,108,946
1,204,605
Balance
Cash
6,910,250
6,904,226
4,702,317
Long term investments
793,283
480,241
1,165,617
Excess cash
6,685,176
6,578,969
5,117,893
Stockholders' equity
18,877,450
14,100,780
10,641,692
Invested Capital
18,217,169
15,470,143
12,480,906
ROIC
38.67%
36.90%
47.99%
ROCE
29.60%
26.18%
32.11%
EV
Common stock shares outstanding
9,250,541
9,229,247
9,054,129
Price
15.82
-33.81%
23.90
-43.47%
42.28
-26.80%
Market cap
146,343,563
-33.65%
220,571,420
-42.38%
382,808,580
-25.72%
EV
148,740,534
222,013,957
386,830,636
EBITDA
9,073,935
6,969,212
6,629,133
EV/EBITDA
16.39
31.86
58.35
Interest
194,823
177,647
164,663
Interest/NOPBT
2.63%
3.06%
2.90%